Champions TumorGraft® Patient-Derived Xenograft (PDX) Models: Predictive, Prospective, Cost-Effective

As our understanding of the complex mechanisms underlying cancer grows, so does the need for extensive translational research. In an era of targeted molecular therapy, the remarkably wide range and heterogeneous expression of genetic modifications in cancer further underscores the need for large cohorts of highly-characterized, clinically relevant PDX models to guide drug development strategies.

Champions Oncology is the solution. Champions TumorGraft technology — based on a platform that replicates human tumors in immunodeficient mice, known as patient-derived xenografts (PDX) — provide models for robust, rigorous translational research that helps shorten development timelines while controlling costs. Highly-characterized, clinically relevant models, a flexible environment, global footprint and forward-thinking vision position Champions Oncology as the ideal partner for your oncology drug development program.

Learn more about how Champions is the right partner in derisking and accelerating the development of your drug.

Champions Oncology - Specializing in | Personalized Cancer Therapy | Translational Oncology Solutions | Oncology drug development | Oncology drug discovery | Translational oncology | Translation oncology research | Predictive oncology | Patient-derived xenograft model | Tumorgrafts | Alternative/new cancer treatment | Anticancer therapies | Personalized cancer treatment | Personalized cancer therapy | Personalized oncology